Form 4: UTHR COO Sells Shares After Option Exercise

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold 22,500 shares of common stock for a significant profit, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), executed a series of transactions on October 20, 2025.
• The transactions involved the exercise of stock options and the subsequent sale of the resulting common stock.
• A total of 14,625 shares were acquired by exercising options at a price of $135.42 per share.
• An additional 7,875 shares were acquired by exercising options at a price of $146.03 per share.
• All 22,500 shares (14,625 + 7,875) were then sold at a price of $427.409 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan, which Mr. Benkowitz entered into on June 3, 2025.
• Following these transactions, Mr. Benkowitz directly holds 2,648 shares of common stock and indirectly holds 70,500 stock options in one trust and 1,750 stock options in another trust.

Sentiment

Score: 7

Explanation: The filing reports a routine, pre-scheduled insider transaction where the executive realized significant gains. This reflects positively on the company's past stock performance and the executive's compensation, without indicating any immediate negative or positive operational news.

Positives

• The President and COO realized substantial personal gains from the exercise of stock options and subsequent sale of shares, indicating a significant increase in the company's stock price since the options were granted.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned diversification or liquidity event rather than a reaction to new, negative information.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The transactions involved shares held in trusts beneficially owned by the Reporting Person. One trust involves the Reporting Person and spouse as co-trustees with shared investment and voting power. Another trust involves the Reporting Person's family members as beneficiaries, with the Reporting Person having sole investment and voting power.

Stakeholder Impact

• Shareholders: The sale by a high-ranking executive, even under a 10b5-1 plan, might be viewed with slight caution by some, but the pre-planned nature and significant profit realized could also be seen as a positive reflection of past stock performance.
• Management: Michael Benkowitz, the President and COO, realized substantial personal financial gains from these transactions.

Key Dates

Recommendation

This filing details a pre-scheduled exercise of stock options and subsequent sale of shares by a key executive under a Rule 10b5-1 trading plan. Such transactions are routine for insiders to diversify holdings and realize gains, and do not typically signal a change in the company's fundamental outlook or warrant a strong buy/sell recommendation based solely on this filing. The significant profit realized by the COO indicates past strong stock performance, but this event itself does not provide new information to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Michael Benkowitz, Insider Trading, Stock Options, 10b5-1 Plan, Share Sale, Executive Compensation